{
    "title": "AstraZeneca shares boosted after pharmaceutical firm hails success of late stage trial of breast cancer drug",
    "url": "https://www.dailymail.co.uk/money/markets/article-11112483/AstraZeneca-shares-rise-trial-success-breast-cancer-drug.html",
    "date": "2022-08-15",
    "keywords": [
        "breast",
        "cancer",
        "drug",
        "trial",
        "month",
        "share",
        "enhertu",
        "approval",
        "fund",
        "ftse",
        "pharma",
        "giant",
        "success",
        "company",
        "use",
        "disease",
        "cent",
        "trade",
        "astrazeneca",
        "lynparza",
        "treatment",
        "risk",
        "investment",
        "account",
        "fee",
        "top",
        "stage",
        "enerthu",
        "form",
        "improvement",
        "ratesthe",
        "class",
        "chemotherapy",
        "tumor",
        "news",
        "morning",
        "monday",
        "business",
        "group",
        "interest",
        "float",
        "haleon",
        "shot",
        "arm",
        "article",
        "test",
        "her2",
        "protein",
        "growth",
        "spread",
        "destinybreast02",
        "head",
        "research",
        "development",
        "sankyo",
        "topline",
        "progressionfree",
        "survival",
        "understanding",
        "benefit",
        "therapy",
        "indication",
        "europe",
        "body",
        "cancerenhertus",
        "commissionlynparza",
        "type",
        "earlystage",
        "phase",
        "june",
        "death",
        "march",
        "diy",
        "capital",
        "isa",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}